David E Thurston

David E Thurston

Company: Femtogenix

Job title: Chief Scientific Officer


New Developments with the Pyridinobenzodiazepine (PDD) ADC Payload 10:00 am

Updates will be presented on ADCs carrying the low-potency PDD G-monoalkylating payload FGX20-75, including its toxicity profile The latest data from work on the high-potency PDD G-monoalkylating payload FGX2-62 will be disclosed. The development of a novel PDD-based payload sufficiently hydrophilic to allow conjugation at high DARs (e.g., DAR 7) will be describedRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.